Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements [Yahoo! Finance]
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result [Yahoo! Finance]